Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP Followed by FOLFIRI vs FOLFIRI Followed by DP in Unresectable Gastric Cancer
NCT00313872Phase 3Completed
- Sponsor
- Samsung Medical Center
- Start
- May 2003
- Primary completion
- Jun 2009
- Modality
- Nanoparticles, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, Cisplatin micelle injection (HA132), irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil in gastric cancer (GC), sponsored by Samsung Medical Center. Started May 2003; status: completed.
02
Drugs
docetaxelCisplatin micelle injection (HA132)irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracil
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00313872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313872.